Literature DB >> 24371499

Orbital complications of fungal pan-sinusitis in uncontrolled diabetes.

Miruna Nicolae1, Cristian Radu Popescu1, Bogdan Popescu1, Raluca Grigore1.   

Abstract

ABSTRACT: The purpose of our clinical case presentation is to emphasize the role of ear, nose and throat specialist in early recognition and urgent treatment of mucormycosis, which is a rare infection caused by fungus belonging to the order Mucorales. They are known opportunistic organisms, which potentially invade and infect a host with depressed immunity. In our paper we present a case of an uncontrolled diabetic male with orbital complications caused by a fungal pan-sinusitis. The typical presentation of rhino-orbital fungal infection is that of anterior orbital inflammation, severe visual loss, external ophthalmoplegia and fever. Our diagnostic was based on an otolaryngological, ophthalmological, imagistic but especially biopsy exam, which is the only one that can make the certain diagnostic in this case. We followed the standard treatment for these situations. Early recognition and treatment with urgent surgical debridement and systemic antifungal therapy is the key to the management of rhino-orbital mucormycosis and is necessary to limit the spread of infection, which can lead to high morbidity and mortality. Therefore, health practitioners should be familiar with the signs and symptoms of the disease.The authors certify that they do not have any financial or personal relationships that might bias the content of this work.

Entities:  

Year:  2013        PMID: 24371499      PMCID: PMC3869119     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  11 in total

1.  Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities.

Authors:  R W Pelton; E A Peterson; B C Patel; K Davis
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2001-01       Impact factor: 1.746

2.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

Authors:  V Rickerts; J Atta; S Herrmann; V Jacobi; E Lambrecht; R Bialek; G Just-Nübling
Journal:  Mycoses       Date:  2006       Impact factor: 4.377

4.  Indications for orbital exenteration in mucormycosis.

Authors:  Roderick N Hargrove; Ralph E Wesley; Kimberly A Klippenstein; James C Fleming; Barrett G Haik
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 Jul-Aug       Impact factor: 1.746

5.  Mucormycosis.

Authors:  D Mohanty; M Dhar; S Dwivedi
Journal:  Trop Doct       Date:  2010-04       Impact factor: 0.731

Review 6.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 7.  Zygomycosis (mucormycosis): emerging clinical importance and new treatments.

Authors:  Richard N Greenberg; Lauren J Scott; Heather H Vaughn; Julie A Ribes
Journal:  Curr Opin Infect Dis       Date:  2004-12       Impact factor: 4.915

Review 8.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Rhino-orbito-cerebral mucormycosis, a retrospective study of 7 cases.

Authors:  Pablo Santos Gorjón; Pedro Blanco Pérez; Angel Batuecas Caletrío; Angel M Muñoz Herrera; Fernando Sánchez González; Rebeca de la Fuente Cañibano
Journal:  Acta Otorrinolaringol Esp       Date:  2009-12-10

10.  Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes.

Authors:  Suneetha Nithyanandam; Moire S Jacob; Ravindra R Battu; Reji K Thomas; Majorie A Correa; Ophelia D'Souza
Journal:  Indian J Ophthalmol       Date:  2003-09       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.